You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

List of Excipients in Branded Drug PROTAMINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing PROTAMINE SULFATE

Excipient Strategy and Commercial Opportunities for Protamines Sulfate

Last updated: March 5, 2026

Protamines sulfate is a protein-based anticoagulant used primarily to reverse the effects of heparin during surgical procedures or dialysis. Its formulation and excipient strategy directly impact drug stability, bioavailability, and manufacturing efficiency, which influence commercial viability.

What Are the Key Excipient Considerations for Protamines Sulfate?

Stabilizers and Buffers

Protamines sulfate solutions require stabilizers that maintain protein integrity. Common buffers include acetate, phosphate, or citrate systems, chosen for their compatibility with protein stability and pH control.

Preservatives

Preservatives are necessary for multi-dose formulations. Chlorobutanol and benzyl alcohol are common, though concerns over toxicity limit their use. Formulating preservative-free options with single-dose packaging could mitigate safety issues.

Solvent and Delivery Medium

Aqueous solutions are standard, with isotonicity adjusted via sodium chloride or mannitol. The choice aims to minimize cell irritation and maintain protein stability.

Lyophilization Components

For freeze-dried formulations, excipients like sucrose, trehalose, or mannitol serve as cryoprotectants, protecting the protein during drying and reconstitution.

How Do Excipient Choices Affect Commercial Opportunities?

Manufacturing Efficiency

Optimizing excipient compatibility reduces batch failures and extends shelf life, leading to cost savings. For example, substituting incompatible buffers with compatible phosphate buffers enhances stability and throughput.

Regulatory Compliance

Use of excipients with established safety profiles simplifies regulatory approval. Excipients like sucrose or sodium chloride have well-documented safety, facilitating faster market entry.

Market Differentiation

Developing preservative-free, single-dose formulations meets patient safety standards and addresses hospital preferences, creating competitive advantage.

Cost and Supply Chain

Selection of globally available excipients reduces supply chain risk and costs. For example, using standard buffers and stabilizers reduces procurement complexity and expense.

Commercial Opportunities Related to Formulation Strategies

Novel Delivery Formats

Developing ready-to-use, lyophilized kits with optimized excipients can expand use in emergency settings and outpatient procedures.

Biosimilar Development

Aligning excipient strategies with approved reference products enables biosimilar manufacturers to expedite approval and capture market share.

Market Expansion

Formulations with improved stability profiles extend shelf life, allowing distribution to emerging markets with less sophisticated cold chain infrastructure.

Patents and Exclusivity

Innovative excipient combinations can be patentable, offering a period of market exclusivity and increased margins.

Regulatory and Patent Landscape

Regulators prioritize safety and efficacy, favoring well-established excipients. Patent filings around specific excipient combinations can extend market exclusivity, but must navigate existing intellectual property.

Summary of Excipient Strategies

  • Use of proven stabilizers such as sucrose or trehalose in lyophilized formats
  • Deployment of preservative-free, single-dose solutions
  • Selection of buffers for pH stability and compatibility
  • Incorporation of excipients that enhance shelf life and ease of manufacturing

Key Takeaways

  • Excipient selection influences stability, safety, and regulatory approval, impacting commercial success.
  • Manufacturing efficiencies and supply chain considerations favor established, globally available excipients.
  • Innovations in formulation—such as preservative-free and lyophilized options—enhance market competitiveness.
  • Patents around excipient combinations can provide market exclusivity, but require careful navigation.
  • Strategic formulation choices support market expansion, especially in emerging regions.

FAQs

1. What are the main excipients used in protamine sulfate formulations?
Buffers such as phosphate, stabilizers like sucrose or trehalose, and preservatives (if multi-dose) such as benzyl alcohol, are typical.

2. How does excipient choice influence the stability of protamine sulfate?
Excipients like sucrose protect the protein during freeze-drying, while buffers maintain optimal pH to prevent degradation.

3. Are there regulatory challenges with excipients in protamine sulfate?
Yes. Using excipients with a well-known safety profile expedites approval; novel excipients require additional safety data.

4. What formulation innovations could expand commercial opportunities?
Developing preservative-free, pre-filled syringes and lyophilized kits enhances safety and convenience for healthcare providers.

5. How can excipient strategies facilitate global market expansion?
Choosing excipients that extend shelf life and are compatible with less controlled storage conditions supports distribution in emerging markets.

References

  1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Stability Testing of Drug Substances and Products. https://www.fda.gov/media/70848/download
  2. Blank, M., & Weiss, A. (2019). Protein Stabilization in Pharmaceutical Formulations. Journal of Pharmaceutical Sciences, 108(3), 877–890.
  3. European Medicines Agency. (2018). Reflection Paper on Formulation of Biological Medicines. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulation-biological-medicines_en.pdf

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.